ANTI TUBERCULOSIS CANDIDATE VACCINE TESTING IN RHESUS MONKEYS

三组猕猴[1对照组，接种QS-21 只接种佐剂；2组接种QS-21+(2剂) 结核分枝杆菌培养滤液蛋白(CFP)] 紧随其后的是临床上的原始细胞生成和血液单核细胞 单元子集分析，同时等待容纳 动物在与活的结核分枝杆菌比赛后。这个空间最近变成了 准备好供我们使用了。我们挑战了另外两只恒河猴(RM) 大约6×106活结核分枝杆菌(H37Rv株)和2个RM 大约100毫巴，以确定用于 疫苗研究中12只动物面临的挑战。2大剂量 RM对旧的结核菌素和临床试验呈阳性 结核病，包括结核杆菌阳性的肺灌洗，在4-6周内； 低剂量的RM还没有进行皮试，也没有 有2个月以上的临床疾病征兆 接种后接种。12只疫苗猕猴将面临1X挑战 106辆山地车。

Three groups of macaques [1 control, vaccinated with QS-21 adjuvant only; and 2 groups vaccinated with QS-21 + (2 doses of) culture filtrate protein (CFP) from Mycobacterium tuberculosis (MTB)] were followed clinically and by blastogenesis and blood mononuclear cell subset analysis while waiting for new space in which to house the animals after challenge with live MTB. The space has recently become ready for our use. We challenged 2 additional rhesus monkeys (RM) with approximately 6 X 106 live MTB (strain H37Rv) and 2 RM with approximately 100 MTB, to determine the appropriate dose for use in the challenge of the 12 animals in the vaccine study. The 2 high-dose RM developed positive skin tests to old tuberculin and clinical tuberculosis, including MTB-positive lung lavages, within 4-6 weeks; the low dose pair of RM have not yet skin test converted nor have they shown signs of clinical disease to date more than 2 months postinoculation. The 12 vaccine macaques will be challenged with 1 X 106 MTB.